Karen A. Gelmon

55.2k total citations · 12 hit papers
393 papers, 23.8k citations indexed

About

Karen A. Gelmon is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Karen A. Gelmon has authored 393 papers receiving a total of 23.8k indexed citations (citations by other indexed papers that have themselves been cited), including 292 papers in Oncology, 125 papers in Cancer Research and 114 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Karen A. Gelmon's work include HER2/EGFR in Cancer Research (117 papers), Breast Cancer Treatment Studies (101 papers) and Cancer Treatment and Pharmacology (96 papers). Karen A. Gelmon is often cited by papers focused on HER2/EGFR in Cancer Research (117 papers), Breast Cancer Treatment Studies (101 papers) and Cancer Treatment and Pharmacology (96 papers). Karen A. Gelmon collaborates with scholars based in Canada, United States and United Kingdom. Karen A. Gelmon's co-authors include Rinat Yerushalmi, Caroline Speers, Ryan Woods, Maggie C.U. Cheang, Torsten O. Nielsen, Hagen F. Kennecke, Stephen Chia, John R. Mackey, Donald C. McKenzie and Ivo A. Olivotto and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Karen A. Gelmon

380 papers receiving 23.2k citations

Hit Papers

Palbociclib and Letrozole in Advanced Breast ... 2007 2026 2013 2019 2016 2010 2010 2007 2011 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Palbociclib and Letrozole in Advanced Breast Cancer
    2016 1.9k citations Richard S. Finn, Hope S. Rugo et al. profile →
  2. Metastatic Behavior of Breast Cancer Subtypes
    2010 1.6k citations Karen A. Gelmon et al. profile →
  3. Ki67 in breast cancer: prognostic and predictive potential
    2010 899 citations Karen A. Gelmon et al. profile →
  4. Effects of Aerobic and Resistance Exercise in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Multicenter Randomized Controlled Trial
    2007 866 citations Karen A. Gelmon et al. profile →
  5. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
    2011 850 citations Karen A. Gelmon, David G. Huntsman et al. profile →
  6. Exemestane for Breast-Cancer Prevention in Postmenopausal Women
    2011 646 citations Karen A. Gelmon, Dongsheng Tu et al. profile →
  7. Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
    2010 456 citations Karen A. Gelmon et al. profile →
  8. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update
    2018 411 citations Karen A. Gelmon et al. profile →
  9. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
    2016 411 citations Karen A. Gelmon, Timothy J. Whelan et al. profile →
  10. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
    2019 286 citations Hope S. Rugo, Richard S. Finn et al. Breast Cancer Research and Treatment profile →
  11. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.
    2022 109 citations Richard S. Finn, Hope S. Rugo et al. profile →
  12. Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer
    2024 81 citations Dennis J. Slamon, Véronique Dièras et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karen A. Gelmon Canada 73 15.9k 7.0k 6.6k 5.6k 2.6k 393 23.8k
George W. Sledge United States 72 14.8k 0.9× 9.6k 1.4× 6.3k 1.0× 7.5k 1.3× 1.7k 0.6× 444 25.4k
Roger A’Hern United Kingdom 75 9.4k 0.6× 5.4k 0.8× 5.2k 0.8× 3.7k 0.7× 2.5k 1.0× 282 20.5k
Vicente Valero United States 94 17.3k 1.1× 13.2k 1.9× 4.9k 0.7× 5.4k 1.0× 2.2k 0.8× 500 27.9k
Antonio C. Wolff United States 71 15.9k 1.0× 10.7k 1.5× 4.9k 0.7× 5.5k 1.0× 1.9k 0.7× 360 24.8k
Julie R. Gralow United States 68 12.5k 0.8× 5.5k 0.8× 4.2k 0.6× 4.0k 0.7× 1.9k 0.7× 283 20.4k
Harold J. Burstein United States 67 11.9k 0.7× 7.1k 1.0× 4.4k 0.7× 2.8k 0.5× 2.3k 0.9× 220 19.1k
Giuseppe Curigliano Italy 79 16.2k 1.0× 7.1k 1.0× 6.3k 1.0× 5.5k 1.0× 1.3k 0.5× 835 26.6k
Carsten Bokemeyer Germany 89 14.2k 0.9× 3.0k 0.4× 9.8k 1.5× 9.5k 1.7× 1.4k 0.5× 957 36.1k
John R. Mackey Canada 84 14.8k 0.9× 4.0k 0.6× 4.6k 0.7× 5.9k 1.0× 1.2k 0.5× 335 24.6k
Edith A. Perez United States 79 20.7k 1.3× 11.1k 1.6× 5.8k 0.9× 6.6k 1.2× 4.4k 1.7× 400 30.1k

Countries citing papers authored by Karen A. Gelmon

Since Specialization
Citations

This map shows the geographic impact of Karen A. Gelmon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen A. Gelmon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen A. Gelmon more than expected).

Fields of papers citing papers by Karen A. Gelmon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen A. Gelmon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen A. Gelmon. The network helps show where Karen A. Gelmon may publish in the future.

Co-authorship network of co-authors of Karen A. Gelmon

This figure shows the co-authorship network connecting the top 25 collaborators of Karen A. Gelmon. A scholar is included among the top collaborators of Karen A. Gelmon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen A. Gelmon. Karen A. Gelmon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gelmon, Karen A., et al.. (2025). Advancing treatment in HER2-positive metastatic breast cancer: the role of tucatinib. Future Oncology. 21(19). 2439–2449.
2.
Agostinetto, Elisa, Georg Pfeiler, Dominik Hlauschek, et al.. (2025). Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109). ESMO Open. 10(1). 104096–104096. 1 indexed citations
3.
Gelmon, Karen A., Jean-François Boileau, Christine Brezden‐Masley, et al.. (2024). Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting. Current Oncology. 31(11). 6536–6567. 1 indexed citations
4.
Gelmon, Karen A., PA Fasching, Suzette Delaloge, et al.. (2023). 203P Clinical effectiveness of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer (mBC) by ER expression level: Subgroup analysis from phase IIIb LUCY trial. ESMO Open. 8(1). 101392–101392. 1 indexed citations
5.
Mariano, Caroline, Tina Hsu, Sarah Cook, et al.. (2023). Key Considerations for the Treatment of Advanced Breast Cancer in Older Adults: An Expert Consensus of the Canadian Treatment Landscape. Current Oncology. 31(1). 145–167.
6.
Hershman, Dawn L., Bingshu E. Chen, Wendy R. Parulekar, et al.. (2023). Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32). Breast Cancer Research and Treatment. 200(1). 93–102. 6 indexed citations
7.
Rayson, Daniel, Sonal Gandhi, Anil A. Joy, et al.. (2022). Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Current Oncology. 29(12). 9891–9895. 2 indexed citations
8.
9.
Finn, Richard S., Massimo Cristofanilli, Johannes Ettl, et al.. (2020). Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. Breast Cancer Research and Treatment. 184(1). 23–35. 25 indexed citations
10.
Dièras, Véronique, Nadia Harbeck, Anil A. Joy, et al.. (2019). Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. The Oncologist. 24(12). 1514–1525. 55 indexed citations
11.
Rugo, Hope S., Richard S. Finn, Véronique Dièras, et al.. (2019). Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Research and Treatment. 174(3). 719–729. 286 indexed citations breakdown →
12.
Drögemöller, Britt I., Beth Brooks, Jose Gerard Monzon, et al.. (2018). Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients. Clinical Cancer Research. 24(8). 1866–1871. 28 indexed citations
13.
Bernstein, Vanessa, Susan Ellard, Susan Dent, et al.. (2017). A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.. Breast Cancer Research and Treatment. 167(2). 485–493. 79 indexed citations
14.
Hurvitz, Sara A., Karen A. Gelmon, & Sara M. Tolaney. (2017). Optimal Management of Early and Advanced HER2 Breast Cancer. American Society of Clinical Oncology Educational Book. 37. 76–92. 16 indexed citations
15.
Macfarlane, Robyn Jane & Karen A. Gelmon. (2010). Lapatinib for breast cancer: a review of the current literature. Expert Opinion on Drug Safety. 10(1). 109–121. 23 indexed citations
16.
Kalra, Jessica, Brent W. Sutherland, Anna L. Stratford, et al.. (2010). Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1. Oncogene. 29(48). 6343–6356. 46 indexed citations
17.
Batist, Gerald, Karen A. Gelmon, Kim N., et al.. (2009). Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors. Clinical Cancer Research. 15(2). 692–700. 166 indexed citations
18.
O’Malley, Frances P., Tom Thomson, Jim A. Julian, et al.. (2008). HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.. Archives of Pathology & Laboratory Medicine. 132(1). 61–5. 23 indexed citations
19.
Giltnane, Jennifer M., Annette M. Molinaro, Huan Cheng, et al.. (2008). Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer.. Archives of Pathology & Laboratory Medicine. 132(10). 1635–47. 32 indexed citations
20.
Münster, Pamela N., Carolyn D. Britten, Monica Mita, et al.. (2007). First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors. Clinical Cancer Research. 13(4). 1238–1245. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by George W. Sledge Breakdown of academic impact, for papers by Roger A’Hern Breakdown of academic impact, for papers by Vicente Valero Breakdown of academic impact, for papers by Antonio C. Wolff Breakdown of academic impact, for papers by Julie R. Gralow Breakdown of academic impact, for papers by Harold J. Burstein Breakdown of academic impact, for papers by Giuseppe Curigliano Breakdown of academic impact, for papers by Carsten Bokemeyer Breakdown of academic impact, for papers by John R. Mackey Breakdown of academic impact, for papers by Edith A. Perez
Rankless by CCL
2026